Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4
Journal Title: Annals of Hepatology - Year 2013, Vol 12, Issue 1
Abstract
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferonplus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have focused on genotype 4 patients, who have had a poor representation in pivotal trials. Our aim was to evaluate the efficacy and safety of treatment with standard dose pegylated interferon alfa-2a in combination with weight-based ribavirin in patients with chronic hepatitis C genotype 4. In this prospective observational study, 198 patients with HCV-4 were included in this study from February 2004 to August 2005,188 patients who received at least 1 dose of drugs were included in the ITT analysis and they were treated with pegylated interferon alfa-2a and ribavirin for 48 weeks. Baseline and demographic characteristics, response to treatment at weeks 12, 48 and 72, and the nature and frequency of adverse effects were analyzed. Virological response at week 12 was achieved in 144 patients (76.6%). Virological response at the end of treatment was present in 110 patients (58.5%). At week 72, 99 patients presented SVR (52.7%). The reported adverse events were similar to those found in the literature for treatments of similar dose and duration. In conclusion, combined treatment with pegylated interferon alfa-2a and ribavirin was well tolerated and effective in chronic hepatitis C genotype 4, yielding response rates between those reported for genotype 1 and those of genotypes 2-3.
Authors and Affiliations
Juan Urquijo, Moisés Diago, Jaume Boadas, Ramón Planas, Ricard Solá, Javier Crespo, José Erdozaín, María Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Ricardo Perez, Blai Dalmau, Miguel Montoro
Keywords
Related Articles
- EP ID EP78228
- DOI -
- Views 112
- Downloads 0
Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico
Introduction. Hepatorenal tyrosinemia (HT1) is a treatable, inherited, metabolic disease characterized by progressive liver failure with pronounced coagulopathy. The aim of this study is to describe the clinical, biochem...
Minimal hepatic encephalopathy in cirrhosis- how long to treat?
Introduction. Minimal hepatic encephalopathy (MHE) can reverse after short-term treatment. However, relapse rate of MHE after stopping treatment has not been studied so far. We aimed to evaluate long-term (9 months) effi...
Meeting the Eastern perspective in hepatitis B related ACLF
Hepatitis E virus: new faces of an old infection
Hepatitis E virus is one of the most common causes of acute hepatitis worldwide, with the majority of cases occurring in Asia. In recent years, however, an increasing number of acute and chronic hepatitis E virus infecti...
The role of zinc in liver cirrhosis
Zinc is an essential trace element playing fundamental roles in cellular metabolism. It acts mostly by binding a wide range of proteins, thus affecting a broad spectrum of biological processes, which include cell divisio...